Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Study to Evaluate the Efficacy and Safety of CKD-350

Phase 3

Conditions: Dry Eye Syndrome

Interventions: Drug: Isotonic 0.3% Sodium Hyaluronate
Drug: Xenobella

First Posted Date: 2016-05-19

Last Posted Date: 2016-05-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 138

Registration Number: NCT02777723

Locations: 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷
The Catholic University of Korea Seoul ST. MARY'S Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 11 locations

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: CKD-519
Drug: placebo

First Posted Date: 2016-04-28

Last Posted Date: 2017-07-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT02753504

Locations: 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of

A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg
Drug: CKD-395 0.25/500mg

First Posted Date: 2016-02-19

Last Posted Date: 2017-08-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 26

Registration Number: NCT02685774

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Korea, Republic of

Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan 16mg
Drug: Amlodipine 5mg
Drug: Amlodipine 10mg

First Posted Date: 2016-01-11

Last Posted Date: 2020-08-25

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 135

Registration Number: NCT02651870

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: Lipitor + Lipidil supra
Drug: CKD-337

First Posted Date: 2016-01-11

Last Posted Date: 2016-07-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 48

Registration Number: NCT02651753

Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T

First Posted Date: 2016-01-07

Last Posted Date: 2016-02-08

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 26

Registration Number: NCT02648854

Locations: 🇰🇷
Chonbuk National University Hospital, Deokjin-gu, Jeonju-si, Jeollabuk-do, Korea, Republic of

Study to Compare the Safety and Pharmacokinetics of CKD-397

Phase 1

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: CKD-397
Drug: TD+TM

First Posted Date: 2016-01-05

Last Posted Date: 2016-01-12

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT02645890

Locations: 🇰🇷
Dong A University Hospital, Seo-gu, Busan, Korea, Republic of

Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

Phase 1

Completed

Conditions: Fungal Infections
Aspergillus Infections
Candida Infections

Interventions: Drug: Vorico Injection 200mg(Voriconazole)
Drug: Vfend®(Voriconazole) IV 200mg

First Posted Date: 2015-12-16

Last Posted Date: 2020-03-18

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT02631954

Locations: 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg
Drug: CKD-395 0.25/750mg

First Posted Date: 2015-12-10

Last Posted Date: 2016-01-06

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 26

Registration Number: NCT02627027

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Korea, Republic of

Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: CKD-519 50mg 2Tabs.
Drug: CKD-519 100mg 1Tab.
Drug: CKD-519 100mg 1Cap.

First Posted Date: 2015-12-08

Last Posted Date: 2016-01-20

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT02623868

Locations: 🇰🇷
Korea university medical center, Seoul, Sungbuk-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy